Zerion Pharma A/S

Zerion Pharma A/S
About Us
Quotes
Change country

Follow us:
Share:
Subscribe:

About Us

ZERION has pioneered the Dispersome® technology that greatly enhances the solubility of poorly soluble, oral drugs and improves bioavailability and the therapeutic options for patients. The Dispersome® technology is based on preparing stable amorphous formulations by mixing high loads of the drug compound with beta-lactoglobulin. ZERION develops proprietary drug formulations and offers the Dispersome® technology to established pharma companies as a means to solve their most challenging drug solubility problems. The Dispersome® technology is patent protected and offers in connection with any pharmaceutical drug many additional years of IP protection. ZERION was established in 2019 as a spinout from the University of Copenhagen based on almost a decade of research. (Dispersome® is a trademark of Zerion Pharma A/S)

Quotes

I'm excited to join ZERION in this important role. I believe the company’s technology holds immense potential, and I'm eager to contribute to the company's growth and innovation.

Carl-Åke Carlsson

We are extremely happy to collaborate with both Bayer and Novartis. It is a great opportunity for ZERION to apply our Dispersome® technology to their drug compounds and we are proud to see that our collaborations resulted in valuable insights and learnings for the further development of the technology. It goes without saying that we are thankful to both Bayer and Novartis for their openness to share these findings with the scientific community. Especially for new technologies such as the Dispersome® technology, it is of utmost importance to publish such findings, which ultimately will help to generate more confidence in the technology.

Korbinian Löbmann, CSO of ZERION.

We believe that ZERION’s technology can offer such benefits and have been very pleased with the results, we have seen thus far. We are happy to announce this collaboration that highlights the capabilities of ZERION in the field of drug formulation and the great team that makes it possible.

Alejandro Delgado, Insud Pharma

Hovione is thrilled to be Zerion´s exclusive partner for the application of Dispersome® to the fields of nutraceuticals and diet supplements. The Dispersome® platform and its enabling ingredient – betalactoglobulin or BLG – afford formulators new options which address unmet needs of the industry.

Jean-Luc Herbeaux, CEO of Hovione

The completion of this supply agreement with Arla Foods Ingredients confirms our excellent collaboration that started in 2018 when we identified BLG as a very promising candidate for use in our Dispersome® technology.

Ole Wiborg

We are extremely pleased to have entered into this partnership with ZERION whom we recognize as a very innovative company in the field of oral drug formulations. ZERION´s proprietary Dispersome® technology builds on a new concept of increasing drug solubility by using natural protein-based excipients. I foresee that this will become a valuable component in HOVIONE’s leading amorphous solid dispersion technology platform.

Jean-Luc Herbeaux, Chief Operating Officer in HOVIONE

These are remarkable results that prove that the drug solubility increase provided by our Dispersome® technology translates into significant improvements in bioavailability. This is not the first time we have demonstrated this critical link, but these results are the most convincing to date and exceeded our expectations

Korbinian Löbmann

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Zerion Pharma and Insud Pharma announce collaboration to develop Dispersome® formulations of marketed drug products

Mon, Aug 29, 2022 12:00 CET

- The two companies have started collaborating on the first two drug products and expect to expand their portfolio. AUGUST 29, 2022 (COPENHAGEN, Denmark). The Danish pharmaceutical company Zerion Pharma A/S (ZERION) and the Spanish pharmaceutical group Insud Pharma, SL today are announcing their collaboration to develop and commercialize drug products applying ZERION’s solubility enhancing Dispersome® technology. ZERION will develop Dispersome® formulations of marketed drug products while INSUD PHARMA will be responsible for the finished product dosage form, the clinical development as

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Quotes

Zerion Pharma and Insud Pharma announce collaboration to develop Dispersome® formulations of marketed drug products

Subscribe

Media